|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600116059 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-05 09:49:23 |
|
注册时间: Date of Registration: |
2026-01-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于时间观疗法的慢性心力衰竭患者疾病进展恐惧方案的构建与应用 |
|
Public title: |
Development and Application of a Fear of Disease Progression Program Based on Time Perspective Therapy for Patients with Chronic Heart Failure |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于时间观疗法的慢性心力衰竭患者疾病进展恐惧方案的构建与应用 |
|
Scientific title: |
Development and Application of a Fear of Disease Progression Program Based on Time Perspective Therapy for Patients with Chronic Heart Failure |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
丁一祺 |
研究负责人: |
周雪梅 |
|
Applicant: |
Yiqi Ding |
Study leader: |
Xuemei Zhou |
|
申请注册联系人电话: Applicant telephone: |
+86 151 9082 4773 |
研究负责人电话:
Study leader's |
+86 138 1522 5143 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2258501414@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
119156719@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
南通市青年东路688号 |
研究负责人通讯地址: |
南通市青年东路688号 |
|
Applicant address: |
688 Qingnian East Road, Nantong City |
Study leader's address: |
688 Qingnian East Road, Nantong City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南通大学附属医院 |
||
|
Applicant's institution: |
Affiliated Hospital of Nantong University |
||
|
研究负责人所在单位: |
南通大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Nantong University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-K315-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南通大学附属医院伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Review Board of the Affiliated Hospital of Nantong University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-09 00:00:00 | ||
|
伦理委员会联系人: |
张妞 |
||
|
Contact Name of the ethic committee: |
Niu Zhang |
||
|
伦理委员会联系地址: |
南通市青年东路688号 |
||
|
Contact Address of the ethic committee: |
688 Qingnian East Road, Nantong City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 513 8505 2390 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南通大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Nantong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
南通市青年东路688号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
688 Qingnian East Road, Nantong City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
南通大学附属医院心血管内科 |
||||||||||||||||||||||
|
Source(s) of funding: |
Department of Cardiology, Affiliated Hospital of Nantong University |
||||||||||||||||||||||
|
研究疾病: |
慢性心力衰竭 |
||||||||||||||||||||||
|
Target disease: |
chronic heart failure |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||
|
研究目的: |
基于时间观疗法构建干预方案,为慢性心衰患者提供一种科学、有效、容易接受的心理护理方法,帮助患者更好地面对疾病、积极配合治疗,降低疾病进展恐惧水平,提高生活质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on Time Perspective Therapy, this intervention protocol is formulated to provide patients with chronic heart failure (CHF) with a scientific, effective, and well-accepted psychological nursing method. It aims to help patients better cope with the disease, actively cooperate with treatment, reduce the level of fear of disease progression, and enhance quality of life. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)符合《中国心力衰竭诊断和治疗指南2024》诊断标准的CHF患者; (2)年龄≥18岁; (3)纽约心脏病协会心功能分级Ⅱ-Ⅳ级; (4)Fop 得分≥34 分; (5)病情允许且知情同意,自愿参加; (6)能够正常沟通交流。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Patients with CHF who meet the diagnostic criteria outlined in the China Heart Failure Diagnosis and Treatment Guideline 2024; (2) Aged >=18 years; (3) New York Heart Association (NYHA) functional class II–IV; (4) Fear of Progression Questionnaire (FoP-Q) score >=34 points; (5) Medically stable, having provided informed consent, and volunteering to participate; (6) Able to communicate normally. |
||||||||||||||||||||||
|
排除标准: |
(1)病情不稳定或急剧恶化 (2)存在严重精神障碍或认知功能障碍; (3)合并严重并发症; (4)参与其他干预研究; (5)语言或文化障碍。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Unstable or acutely deteriorating condition; (2) Presence of a severe psychiatric disorder or cognitive impairment; (3) Serious concurrent complications; (4) Participation in other interventional studies; (5) Language or cultural barriers. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-10 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-10 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由组员采用掷硬币法将两个病区随机分为干预组和对照组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The two wards will be randomly assigned to the intervention and control groups by team members using a coin toss method. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
受试者和评估者双盲,患者在试验过程中不知自己被分配至对照组或干预组,负责数据收集与统计分析的人员对受试者的分组信息保持盲态 |
|
Blinding: |
A double-blind design will be implemented, wherein the patients will be unaware of their group assignment (control/intervention), and the staff collecting data and performing statistical analysis will be kept blind to group allocation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
resman临床试验公共管理平台:http://www.medresman.org.cn/login.aspx,研究完成后6个月 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The trial data will be preserved on the ResMan Clinical Trial Public Management Platform (http://www.medresman.org.cn/login.aspx) for 6 months following completion of the study. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据由量表及病例采集,由医院电子采集系统管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data will be collected from scales and medical records, and managed by the hospital's electronic data capture (EDC) system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |